Table 1.
Baseline characteristics of the study population.
| aABOc/XM+ | aABOi/XM+ | P-value | |
|---|---|---|---|
| Number of patients | 176 (66.9) | 87 (33.1) | |
| Mean age (years) | 48.7 ± 11.9 | 51.4 ± 9.6 | 0.12 |
| Female sex | 46 (26.1) | 42 (48.3) | <0.01 |
| Body mass index (kg/m2) | 22.2 ± 3.1 | 25.5 ± 13.5 | 0.06 |
| Calcineurin inhibitor | |||
| Prograf | 151 (85.8) | 74 (85.1) | 0.87 |
| Cyclosporin | 25 (14.2) | 13 (14.9) | |
| Induction | 0.24 | ||
| ATG | 30 (17.0) | 10 (11.5) | |
| Basiliximab | 146 (83.0) | 77 (88.5) | |
| Previous transplant | 28 (25.9) | 19 (21.8) | 0.22 |
| Duration of dialysis (months) | 23.6 ± 36.3 | 29.8 ± 37.3 | 0.33 |
| Cross-matching results | 0.91 | ||
| CDC positive | 14 (8.0) | 8 (9.2) | |
| FCXM positive | 162 (92.0) | 79 (90.8) | |
| T-flow only positive | 83 (47.2) | 39 (44.8) | |
| T- or B- flow positive | 79 (44.9) | 40 (46.0) | |
| PRA class I | 42.3 ± 38.0 | 25.4 ± 34.1 | <0.01 |
| PRA class II | 35.3 ± 38.4 | 30.2 ± 39.7 | 0.36 |
| Maximal DSA (MFI) | 7266 ± 4742 | 7187 ± 4923 | 0.94 |
| DSA class I (MFI) | 5486 ± 4356 | 3705 ± 4654 | 0.09 |
| DSA class II (MFI) | 5088 ± 5522 | 5209 ± 5576 | 0.93 |
Continuous data are presented as means ± standard deviations, whereas categorical data are presented as numbers (%).
Abbreviations: ATG, anti-thymocyte globulin; CDC, complement-dependent cytotoxicity; FCXM, flow-cytometric crossmatch; PRA, panel reactive antibody; DSA, donor specific antibody; MFI, mean fluorescence intensity.
aCrossmatch-positive (XM+) defined as FCXM-positive or CDC XM-positive; ABOc, ABO compatible; ABOi, ABO incompatible.